Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline welcomes potential elephantiasis elimination

GlaxoSmithKline welcomes potential elephantiasis elimination

24th March 2006

GlaxoSmithKline (GSK) has welcomed the news that the disease commonly known as elephantiasis, lymphatic filariasis (LF), could be eliminated.

Evidence reported in the Lancet’s March 25th issue has revealed that the disease that has existed for centuries could finally be eradicated in most areas of Egypt following five years of mass drug administration.

According to GSK, the disease currently threatens one billion people in 83 countries worldwide, but the system of providing diethylcarbamazine plus albendazole once a year for five years seems to be addressing the threat in Egypt.

“The Egypt data shows that we can now eliminate a disease that has plagued the world for centuries,” said JP Garnier, chief executive officer of GSK.

“We remain committed to donating as much albendazole as required to eliminate this disabling disease, but ultimate success will depend on continued long-term commitments by all partners across the globe.”

The Global Alliance to Eliminate LF was formed to help countries with an LF threat combat the problem and will meet in Fiji next week to discuss the future combating of the disease following this major breakthrough.

track© Adfero Ltd

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.